Article Dans Une Revue Resuscitation Plus Année : 2025

Hydrocortisone and arginine vasopressin in post-resuscitation shock: the HYVAPRESS trial

Résumé

Despite advancements in prehospital management and standardization of advanced life support through wide diffusion of international guidelines, the overall prognosis of patients who suffered cardiac arrest (CA) remains poor. About 20 up to 30% of patients admitted to the hospital after a successful resuscitation of out-of-hospital CA are discharged alive and free from significant neurological impairment 1,2 .For in-hospital CA, the survival rate reaches approximately 25%, although patients who experience CA in non-monitored units such as medical and surgical wards have the worst outcomes, with survival rates below 5%. 3 This high early mortality rate is attributed to the concept of post-resuscitation syndrome, typically divided into two consecutive phases: an initial reperfusion injury leading to multiple organ failure and subsequent poor neurological outcomes resulting from anoxic brain injury. 4

Fichier principal
Vignette du fichier
Geri Resus Plus 2025.pdf (754.14 Ko) Télécharger le fichier

Dates et versions

hal-05096781 , version 1 (04-06-2025)

Licence

Identifiants

Citer

Guillaume Geri, Jean-Baptiste Lascarrou, Bruno Levy, Pierre Asfar, Grégoire Muller, et al.. Hydrocortisone and arginine vasopressin in post-resuscitation shock: the HYVAPRESS trial. Resuscitation Plus, 2025, 24, pp.100982. ⟨10.1016/j.resplu.2025.100982⟩. ⟨hal-05096781⟩
1404 Consultations
139 Téléchargements

Altmetric

Partager

  • More